not shown) were maintained in both muscles and spleen. As in the transplantation models, other leukocytes that are CD45RC high and TCR -, such as macrophages and B cells were not depleted by anti-CD45RC treatment (Fig. 6C ).
7 5
At week 12 the animals were analyzed using a grip test. As previously reported 3 , Dmd mdx rats 2 7 6
had a 30% reduction in forelimb strength compared to WT littermates (Fig. 6D) with anti-CD45RC neither modified this curve (Fig. 6E) , nor the general aspect of the skeletal Thus, anti-CD45RC treatment resulted in increased muscle strength in Dmd mdx rats and it was Treatment with prednisolone improved skeletal muscle strength but had secondary 2 9 1 effects.
9 2
Since CS are standard treatment in DMD patients 6 , we analyzed the clinical effect of and spleen of Dmd mdx rats.
9 5
Prednisolone-treated rats also showed at 12 weeks of age a significant decrease of were significantly decreased in spleen but not in muscle (Fig. 7B) . CD4 + CD45RC low T cells 2 9 9
were also decreased in the spleen but not in the muscle (Fig. 7B ). Other leukocytes that are Simultaneously, Dmd mdx rats treated with prednisolone showed significantly increased muscle 3 0 3 strength at 12 weeks to levels identical to those of WT or anti-CD45RC-treated rats (Fig. 7D ).
0 4
Prednisolone-treated Dmd mdx rats showed marked secondary effects, as shown by a severe 3 0 5
(25%) and significant reduction in growth as compared to WT rats but also to NaCl-treated 3 0 6
Dmd mdx rats (Fig. 7E) . Prednisolone had no effect on the growth of WT animals ( Fig. 7E) .
0 7
Muscle tissue fibrosis (Supplementary figure 4A-B) and CK levels in serum 3 0 8
(Supplementary figure 4C) were not modified by prednisolone treatment. Thus, as compared to anti-CD45RC treatment, prednisolone also increased muscle strength Presence of T CD45RC high cells in skeletal muscles and blood of DMD patients.
1 5
To further explore the potential of CD45RC as an immunotherapeutic target, we evaluated the young individuals hospitalized for pathologies not involving the immune system or other from DMD patients were all CD45RC high whereas monocytes and PMN were all CD45RC Furthermore, the presence of CD45RC brightly positive cells was confirmed in muscle
biopsies from DMD patients and not of normal individuals, as it was the case in muscles of
Dmd mdx vs. WT animals (Fig. 8 ). treatments that DMD patients receive and that prolong ambulation by about 2 years. Nevertheless, increase muscular strength responses are variable, incomplete and always
associated to serious side effects 6, 7 . Despite that the precise mechanisms of action of CS in also the case in rats that were tolerant to transplanted organs after anti-CD45RC MAb strength observed in these animals remains to be analyzed in future studies. As for the anti-CD45RC treatment, corticosteroids resulted in a similar increase in muscular
strength that was associated surprisingly to a specific decrease in CD8 + CD45RC high T cells in The secondary effects of steroids were observed in Dmd mdx rats, whereas anti-CD45RC stimulate the use of these other reagents. Animal experiments and ethical aspects. efforts were made to minimize suffering. The rats were housed in a controlled environment Pooled cells were then applied to 15 ml Histopaque 1077density gradient (Eurobio) and
centrifuged at 1000 x g for 30min. The cells at the interface were collected, washed,
resuspended in PBS FCS 2% 1mM EDTA and counted. Spleen was harvested, perfused with collagenase D, minced and incubated for 15 min at 37°C.
5 7
Spleen fragments were then scraped in the presence of PBS FCS 2% 1mM EDTA and Staining of rat cells for flow cytometry analysis.
Cytofluorimetry analysis was performed as previously described in detail
32
. Briefly, single- (clone OX33), CD45R/B220 in B cells (clone His24), anti-granulocytes (RP-1 and His48), Serum creatinine phosphokinase and cytokine levels. Blood was collected under anesthesia, serum was isolated and immediately frozen at -20°C. Total creatinine phosphokinase (CK) activity was determined in the biochemistry department
of Nantes University Hospital.
Levels of IL-1β, IL-6, IL-10 and TNFα in the serum of Dmd mdx or WT littermate rats, were and quality analysis were done on Caliper LabChip GX II (PerkinElmer). RNA with a quality
score between 7 and 10 were retro-transcribed using oligo-dT and M-MLV reverse manufacturer's instructions. qPCR reaction conditions were 20 seconds at 95°C followed by Immunohistological analysis and fibrosis quantification.
9 6
Immunohistochemistry was performed as previously described in detail 3 . Briefly, tissue 4 9 7
samples of Biceps femoris and cardiac ventricular muscles were harvested at 8 and 12 weeks (InVitroGen, Carlsbad, CA) were respectively used to reveal CD3 and CD68 primary 5 0 7
antibody (1 h, room temperature). Section were incubated with wheat germ agglutinin Alexa
Fluor 555 conjugate for connective tissue labelling (Molecular Probes, Eugene, OR)
diluted 1:700 in PBS (overnight, 4°C) and nuclei were then labelled with Draq5 (BioStatus
Ltd, Shepshed, UK) diluted at 1:1000 (10min, room temperature). Immunofluorescence
labeling was analyzed with a laser scanning confocal microscope (Zeiss, LSM880, Jena,
Germany).
For human muscle, biopsies were obtained from DMD patients undergoing surgery for spinal was frozen, sectioned and processed as described above for rat tissue using an anti-human
CD45RC MAb (BD Biosciences). Treatment with anti-CD45RC and prednisolone. administered by daily intraperitoneal injections of 0.5 mg/kg, close to the dose of 1 mg/kg in high granularity using side scatter (SSC high ) CD68 + cells after gating on viable (negatively- several experiments performed using all groups of animals in each experiment. all groups of animals in each experiment. with Draq5 to label nuclei (blue), with wheat germ agglutinin for connective tissue (red) and
with MAbs for detection of cells expressing CD3, CD68 or CD163 (green). Scale bar 5 9 1 identical for all pictures: 100 µm. A) Mononuclear cells from skeletal muscles were harvested at 8 and 12 weeks of age from
wild-type (WT) and Dmd mdx (KO) rats. Total RNA was extracted and mRNA levels for the p<0.05. (lower panels) cells per gram of skeletal muscle (left panels) and of total spleen (right panels). importantly ***p<0.001 between Dmd mdx rats NaCl vs. prednisolone. anti-rat or human anti-CD45RC MAbs (green). panels) or spleen (right panels) from animals at 12 weeks of age. simultaneously in all samples. WT (n=8, 6, 6, 9, 5 at 2, 4, 8, 12 and 16 weeks, respectively),
Dmd mdx (n=5, 4, 8, 8, 6 at 2, 4, 8, 12 and 16 weeks, respectively). * p<0.05. collagenase, mononuclear cells were isolated using a density gradient and analyzed by (left panels) or spleen (right panels) of WT or Dmd mdx rats from animals at 12 weeks of age. Representative picrosirius (purple) staining for animals of the indicated group treatments. C)
(left panel) Sera of Dmd mdx and WT rats treated with prednisolone or vehicle (NaCl) were 11:e0155944. [26] Andreetta F, Bernasconi P, Baggi F, Ferro P, Oliva L, Arnoldi E, Cornelio F,
Mantegazza R, Confalonieri P: Immunomodulation of TGF-beta 1 in mdx mouse inhibits 8 0 9
connective tissue proliferation in diaphragm but increases inflammatory response: [29] Gregori S, Mangia P, Bacchetta R, Tresoldi E, Kolbinger F, Traversari C, Carballido JM,
de Vries JE, Korthauer U, Roncarolo MG: An anti-CD45RO/RB monoclonal antibody reversal of renal allograft rejection by antibody against CD45RB. Nature 1996, 380:717-20. [32] Menoret S, Fontaniere S, Jantz D, Tesson L, Thinard R, Remy S, Usal C, Ouisse LH,
Fraichard A, Anegon I: Generation of Rag1-knockout immunodeficient rats and mice using [33] Bezie S, Picarda E, Tesson L, Renaudin K, Durand J, Menoret S, Merieau E, Chiffoleau 10:e0119686. Primer name Sequence CCAACTCTTGGGAAGACACCA  GTGATGCCCCAGATGACTTT  GACCAAACTGTGTGCCTGGA  TACTCTGAGGGCTGACACAAGG  CCACAGCTCGACAGCATGTC  GTTTCGCTCTATCTCCTCTTCCA  AGTGTCATCGAATCGCACCTG  TTCTGGTGACAGCTGGTGAAT  GCAAGAGACTTCCAGCCAGTT  CATCATCGCTGTTCATACAATCA  CTTCTCATTCCTGCTCGTGG  GCTACGGGCTTGTCACTCG  CTCAACACCTGCACAGCTCC  ACGATCATGTTGGACAACTGCT  TGCTATGTTGCCTGCTCTTACTG  TCAAATGCTCCTTGATTTCTGG  CTGGCTGTCCTCTACCCTGA  TGTCGTGGCAAGATATGGCAA  AGATCGCGTTAGCAGCCATAA  TCAGCTAGGCTATGGCATGTG  ACCTGTCCTGTGTGATGAAAGACG  CTGCTTGAGAGGTGCTGATG  GCTGCCTCCCATTCTGTCTT  TGCGATTTCCACCATTAGAGAG  CTGCGGTCGGGAGTTCATC  CCAGGTGGTCTGTATTGGCTT 
